Coronary Sinus Reducer an Option for Intractable Angina?
Medscape,
ATLANTA, GA — Despite failing to increase perfusion as hypothesized, a coronary sinus reducer (CSR) in a sham-controlled…
ATLANTA, GA — Despite failing to increase perfusion as hypothesized, a coronary sinus reducer (CSR) in a sham-controlled…
Follow Summary I generally like CVR and this is no exception. The CVR is not a sure thing but it does appear to be undervalued…
NASDAQ, TSX: NVCN VANCOUVER, March 19, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN)…
VANCOUVER, /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of…